• Clinical Insights: June 30, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval No new updates.   New Drug Shortage June 21, 2017 Cromolyn Sodium Inhalation Solution, USP (Currently in Shortage) New… Read more »

  • Clinical Insights: June 23, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Bevyxxa™ (betrixaban) – June 23, 2017 – The U.S. Food and Drug Administration approved betrixaban (Bevyxxa™, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients… Read more »

  • Clinical Insights: June 16, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Fibryna® (fibrinogen – [human]) – June 7, 2017 – A human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and adolescents with congenital… Read more »

  • Clinical Insights: June 2, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Rebinyn® (Coagulation Factor IX (Recombinant), GlycoPEGylated) – May 31, 2017 – Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application… Read more »

  • Clinical Insights: May 26, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Kevzara® (sarilumab) – May 22, 2017 – Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of… Read more »

  • Clinical Insights — January Issue 1

    Welcome to the January 2017 edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Spinraza™ (nusinersen) – December 23, 2016 – The U.S. Food & Drug Administration (FDA) approved Spinraza™ (nusinersen), the first drug approved to treat children and adults with… Read more »

  • Clinical Insights — September 2016 Issue

    Welcome to the September edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Amjevita™ (adalimumab-atto) – September 23, 2016 – The U.S. Food and Drug Administration (FDA) approved Amjevita™ (adalimumab-atto) as a biosimilar to Humira® (adalimumab) for multiple inflammatory diseases. Read More.… Read more »

  • Clinical Insights — August 2016 Issue

    Welcome to the August edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Adlyxin™ (lixisenatide) – July 28, 2016 – The U.S. Food and Drug Administration approved Adlyxin™ (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with… Read more »

  • Clinical Insights — April 2016 Issue

    Welcome to the April edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Venclexta™ (venetoclax) April 11, 2016 – The U.S. Food and Drug Administration approved Venclexta™ (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who… Read more »

  • Clinical Insights — March 2016 Issue

    Welcome to the March edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Briviact® (brivaracetam)  February 19, 2016 – The U.S. Food and Drug Administration (FDA) approved Briviact® (brivaracetam) as an add-on treatment to other medications to treat partial onset… Read more »